Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-25

FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, expanding or updating its approve…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vyvanse (lisdexamfetamine dimesylate)

Snippet

SUPPL AP for VYVANSE (LISDEXAMFETAMINE DIMESYLATE)